Firstly, patent prosecution can take a long time – often years. So if, for example, Neuren were to outlicense ROW rights for trofinetide soon after Phase 3 results are announced, this patent may not yet be granted. But even so, this patent application is still important, imo.
Neuren is named as the applicant on this patent. Corden Pharma of Belgium and Switzerland (Peptisyntha parent company), Acadia and all the inventors are recorded in recent documents as assigning their rights to Neuren. Therefore, Neuren owns this patent.
Potentially, I see two main benefits in this patent application.
Firstly, there is the potential to extend the patent protection for trofinetide. Simply, the longer the patent protection, the more valuable the asset.
Secondly, a way has been found to produce trofinetide more efficiently. Obviously, the ability to manufacture “substantially larger quantities” of the drug allows a larger market to be served. Potentially, it may also mean faster manufacturing and cheaper COGs, either adding to the bottom line or allowing savings for the end user.
Wrt ROW rights, I would think that these benefits would make trofinetide an even more attractive/valuable asset to potential licensees.
The potential impact on NNZ-2591 is less clear but I would think that there’s a good chance that these more efficient manufacturing methods (and consequential economic benefits) could apply to NNZ-2591 as well.
Only my opinion and speculation….
NEU Price at posting:
$1.37 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)